Practicing pathology in the era of big data and personalized medicine

Applied Immunohistochemistry and Molecular Morphology

Volumn 22, Issue 1, 2014, Pages 1-9

  Gu, Jiang ^a   Taylor, Clive R ^b  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

advanced personalized diagnostics; big data; companion diagnostics; diagnostic molecular pathology; digital pathology; genomics; immunohistochemistry; liquid morphology; mass spectrometry; metabolomics; molecular pathology; morphologic classification; nextgeneration sequencing; PCR; personalized medicine; predictive markers; proteomics; surgical pathology; targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORPHOLOGY; DISEASE CLASSIFICATION; DNA SEQUENCE; ELECTRONIC MEDICAL RECORD; HISTOPATHOLOGY; HUMAN; MOLECULAR PATHOLOGY; PATHOLOGIST; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION;

HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; PATHOLOGY;

EID: 84891683794     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0000000000000022     Document Type: Review

References (49)

1. Gu J. Computerized three-and four-dimensional modeling of biomedical images for morphologists and pathologists. Cell Vision. 1997;4:6-15. (Pubitemid 27201515)
2. Taylor CR, Cote RJ. Immunomicroscopy: A diagnostic tool for the surgical pathologist. 3rd ed. Philadelphia: Elsevier Saunders; 2005.
3. Taylor CR. From microscopy to whole slide digital images: a century and a half of image. Appl Histochem Mol Morph. 2011;19: 491-493.
4. Catalogue of Somatic Mutations in Cancer (COSMIC). Cell line project. Available at: http://www.cancer.sanger.ac.uk/. Accessed October 20, 2013.
5. Beadling C, Heinrich MC, Warrick A, et al. Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. JMol Diagn. 2011;13:504-513.
6. Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol. 2011;8:184-187.
7. Gerstein MB, Kundaje A, Hariharan M, et al. Architecture of the human regulatory network derived from ENCODE data. Nature. 2012;489:91-100.
8. Chen R, Mias GI, Li-Pook-Than J, et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell. 2012;148: 1293-1307.
9. Taylor CR. Whole slide imaging-issues for use in diagnostic pathology: "routine;" stains, immunohistochemistry and predictive markers. Biotehnics and Histochem. 2013. In press.
10. Walk EE. The role of pathologists in the era of personalized medicine. Arch Pathol Lab Med. 2009;133:605-610.
11. Tonellato PJ, Crawford JM, Boguski MS, et al. A national agenda for the future of pathology in personalized medicine: report of the proceedings of a meeting at the Banbury Conference Center on genome-era pathology, precision diagnostics, and preemptive care: a stakeholder summit. Am J Clin Pathol. 2011;135:668-672.
12. Matloff E, Caplan A. Direct to confusion: lessons learned from marketing BRCA testing. Am J Bioeth. 2008;8:5-8.
13. Hogarth S, Javitt G, Melzer D. The current landscape for direct-toconsumer genetic testing: legal, ethical, and policy issues. Annu Rev Genomics Hum Genet. 2008;9:161-182.
14. Taylor CR, Levenson RM. Quantification of immunohistochemistry-issues concerning methods, utility and semiquantitative assessment II. Histopathology. 2006;49:411-424. (Pubitemid 44401549)
15. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321: 1807-1812.
16. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330-337.
17. Williams ES, Hegde M. Implementing genomic medicine in pathology. Adv Anat Pathol. 2013;20:238-244.
18. Crowley E, Di Nicolantonio F, Loupakis F, et al. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013; 10:472-484.
19. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368:1199-1209.
20. Dunn BK, Jegalian K, Greenwald P. Biomarkers for early detection and as surrogate endpoints in cancer prevention trials: issues and opportunities. Recent Results Cancer Res. 2011;188:21-47.
21. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339:1546-1558.
22. Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science. 2011;331:1553-1558.
23. Stephens PJ, Tarpey PS, Davies H, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012;486: 400-404.
24. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801-1806.
25. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318:1108-1113. (Pubitemid 350134889)
26. Parsons DW, Li M, Zhang X, et al. The genetic landscape of the childhood cancer medulloblastoma. Science. 2011;331:435-439.
27. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007;446:153-158. (Pubitemid 46398669)
28. Pleasance ED, Stephens PJ, O'Meara S, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature. 2010;463:184-190.
29. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455:1069-1075.
30. Kunkel TA. Evolving views of DNA replication (in)fidelity. Cold Spring Harbor Symposia on Quantitative Biology. 2009;74:91-101.
31. Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008;358: 2039-2049. (Pubitemid 351656458)
32. Perrimon N, Pitsouli C, Shilo BZ. Signaling mechanisms controlling cell fate and embryonic patterning. Cold Spring Harbor Perspectives in Biology. 2012;4:a005975.
33. Chung AS, Ferrara N. Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol. 2011;27:563-584.
34. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502: 333-339.
35. Taylor CR, Becker KF. Liquid morphology: immunochemical analysis of proteins extracted from formalin fixed paraffin embedded tissues: combining proteomics with immunohistochemistry. Appl Immunohistochem Mol Morphol. 2011;19:1-9.
36. Jones S, Chen WD, Parmigiani G, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci USA. 2008;105:4283-4288. (Pubitemid 351754372)
37. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467: 1114-1117.
38. Colditz GA, Wolin KY, Gehlert S. Applying what we know to accelerate cancer prevention. Sci Transl Med. 2012;4:127rv124.
39. Pelizzola M, Ecker JR. The DNA methylome. FEBS Lett. 2011; 585:1994-2000.
40. Stuart D, Sellers WR. Linking somatic genetic alterations in cancer to therapeutics. Curr Opin Cell Biol. 2009;21:304-310.
41. Kirkwood JM, Butterfield LH, Tarhini AA, et al. Immunotherapy of cancer in 2012. CA Cancer J Clin. 2012;62:309-335.
42. Incorvati JA, Shah S, Mu Y, et al. Targeted therapy for HER2 positive breast cancer. J Hematol Oncol. 2013;6:38.
43. Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-smallcell lung cancer-is it becoming a reality Nat Rev Clin Oncol. 2010; 7:401-414.
44. Taylor CR. Quantifiable internal reference standards for immunohistochemistry; the measurement of quantity by weight. Appl Immunohistochem Mol Morph. 2006;14:253-259. (Pubitemid 44319049)
45. Hewitt SM, Robinowitz M, Bogen SA, et al. Quality Assurance for Design Control and Implementation of Immunohistochemistry Assays: Approved Guidelines. 2nd ed. Wayne, PA: Clinical Lab Standards Institute; 2011.
46. Taylor CR. Focus on Biospecimens: the issue is the tissue. Observations on the "NCI-NIST fitness for purpose quality assessment and standards workshop". October 2010. Appl Histochem Mol Morph. 2011;19:95-98.
47. Shi SR, Balgley BM, Taylor CR. Symbiosis of Immunohistochemistry and Proteomics: Marching to a New Era. In: Shi S-R, Taylor CR, eds. Antigen Retrieval Immunohistochemistry Based Research and Diagnostics. Hoboken, NJ: JohnWiley and Sons, Inc.; 2010:391-398.
48. Shi SR, Taylor CR, Fowler CB, et al. Complete solubilization of formalin-fixed paraffin embedded tissues may improve proteomic studies. Proteomics Clin Appl. 2013. doi.10.1002.prca.201200031.
49. Rekhtman N, Tafe LJ, Chaft JE, et al. Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma. Mod Pathol. 2013;26:511-522.